Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

B7937

Sigma-Aldrich

BSc3094 monohydrobromide

≥98% (HPLC)

Synonym(e):

2-[4-(4-Nitrophenyl)-2-thiazolyl]hydrazide-1H-benzimidazole-6-carboxylic acid monohydrobromide

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C17H12N6O3S·HBr
CAS-Nummer:
1173021-98-1
Molekulargewicht:
461.29
MDL-Nummer:
MFCD12912398
UNSPSC-Code:
12352200
PubChem Substanz-ID:
329773303
NACRES:
NA.25

Qualitätsniveau

100

Assay

≥98% (HPLC)

Form

solid

Lagerbedingungen

protect from light

Löslichkeit

DMSO: 22 mg/mL

Lagertemp.

2-8°C

SMILES String

Br.[O-][N+](=O)c1ccc(cc1)-c2csc(NNC(=O)c3ccc4[nH]cnc4c3)n2

InChI

1S/C17H12N6O3S.BrH/c24-16(11-3-6-13-14(7-11)19-9-18-13)21-22-17-20-15(8-27-17)10-1-4-12(5-2-10)23(25)26;/h1-9H,(H,18,19)(H,20,22)(H,21,24);1H

InChIKey

HVNYYJJWBWMGCO-UHFFFAOYSA-N

Anwendung

BSc3094 is used in tau protein amyloidogenicity/tauopathy research to study the processes of tau aggregation and cross-linking in neurodegenerative disease development.

Biochem./physiol. Wirkung

BSc3094 is a potent inhibitor of tau aggregation and dissolves preformed tau paired helical filaments. BSc3094 interacts closely with the tau protein at the edge involving protons I-IV, while the second attachment site seems to be at the nitro group. In N2A cells (model system for tau aggregation), BSc3094 exhibited low toxicity.

Piktogramme

Exclamation mark
GHS07

Signalwort

Warning

H-Sätze

H302,H319

Gefahreneinstufungen

Acute Tox. 4 Oral - Eye Irrit. 2

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Chronis Fatouros et al.
Human molecular genetics, 21(16), 3587-3603 (2012-05-23)
Increased Tau protein amyloidogenicity has been causatively implicated in several neurodegenerative diseases, collectively called tauopathies. In pathological conditions, Tau becomes hyperphosphorylated and forms intracellular aggregates. The deletion of K280, which is a mutation that commonly appears in patients with frontotemporal
M Pickhardt et al.
Current Alzheimer research, 4(4), 397-402 (2007-10-03)
Cell models of tauopathy were generated in order to study mechanisms of neurodegeneration involving abnormal changes of tau. They are based on neuroblastoma cell lines (N2a) that inducibly express different forms of the repeat domain of tau (tau(RD)), e.g. the
Luc Buée et al.
Biochemical Society transactions, 38(4), 967-972 (2010-07-28)
Tau pathology is characterized by intracellular aggregates of abnormally and hyperphosphorylated tau proteins. It is encountered in many neurodegenerative disorders, but also in aging. These neurodegenerative disorders are referred to as tauopathies. Comparative biochemistry of the tau aggregates shows that

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.